
Opinion|Videos|June 26, 2024
Efficacy and Safety Trials Results of Complement Inhibitors
Expert panelists evaluate results regarding complement inhibitor trials for utilization in PNH management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Several complement inhibitors have been approved since eculizumab, including ravulizumab, a long-acting C5 inhibitor; danicopan, a factor D inhibitor; pegcetacoplan, a complement C3 inhibitor; and iptacopan, a complement factor B inhibitor. Please discuss the efficacy and safety results from the pivotal trials for each of these treatments.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits
2
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
3
After Narrow Miss in Phase 3 Study, IO Biotech Ponders Next Steps for Immune-Modulatory, Off-the-Shelf Cancer Vaccine
4
Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability
5